Prophylaxis in patients with von Willebrand disease: who, when, how?
A B Federici
https://pubmed.ncbi.nlm.nih.gov/26081061/Actively Recruiting
Led by Bleeding and Clotting Disorders Institute Peoria, Illinois · Updated on 2026-04-03
40
Participants Needed
12
Research Sites
35 weeks
Total Duration
Von Willebrand Disease VWD is the most common inherited bleeding disorder, affecting up to 0.1% of people. It often causes mucous membrane bleeding, heavy menstrual bleeding, surgical bleeding, or other bleeding challenges. Severe cases require treatment with von Willebrand factor VWF concentrates given intravenously. This study is evaluating emicizumab, a monoclonal antibody given by subcutaneous injection, as a potential prophylactic treatment for severe VWD and patients with both VWD and hemophilia A. Participants will receive emicizumab starting with a loading dose of 3 mgkg once weekly for 4 weeks, followed by a maintenance dose of 1.5 mgkg once weekly for one year. Dose escalation to 3 mgkg weekly may occur after 24 weeks if bleeding control is insufficient. Breakthrough bleeding can be treated with usual therapies such as antifibrinolytics or VWFFVIII concentrates. The study is open-label and will collect treatment records and bleeding logs throughout. Participants will be monitored for efficacy and safety over 18 months, including patient-reported outcomes on quality of life, physical, emotional, social, and general symptoms. Data on annualized bleed rates and treatment burden compared to previous therapies will be collected. Safety assessments and adherence to emicizumab prophylaxis will be tracked as well. This includes a one-year retrospective review of bleeding history before starting treatment.
CONDITIONS
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
M
Megan L Woodbury, PhD
D
Dayna Lenski, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Bleeding and Clotting Disorders Institute Peoria, Illinois
Lead Sponsor
Genentech, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Emicizumab Prophylaxis (Investigational in VWD/hemophilia A) | VWF-containing Factor VIII Prophylaxis (Standard Care) |
|---|---|---|
| What it is | A bispecific monoclonal antibody that mimics factor VIII function, administered as a subcutaneous injection for prophylaxis to reduce bleeding in people with severe VWD or VWD/hemophilia A. | A purified concentrate containing both Von Willebrand Factor and factor VIII, given by intravenous infusion to support clotting and prevent bleeding episodes in people with severe VWD or VWD/hemophilia A. |
| Role in trial | All enrolled participants receive emicizumab prophylaxis as their only routine bleed-prevention treatment during the study period. | Not part of this trial but represents the established approach used outside the study for continuous prophylaxis in similar patients. |
| Primary use | Reducing the frequency and severity of bleeding episodes in patients with severe VWD or those with both VWD and hemophilia A who need prophylaxis. | Routine prevention of spontaneous and trauma-related bleeding in people with severe VWD and related complicated forms, especially when desmopressin is ineffective or not recommended. |
| How it is given or performed | Given as a subcutaneous injection according to a study-defined schedule, typically on a regular basis (e.g., weekly or biweekly), after stopping previous prophylaxis. | Administered as an intravenous infusion, usually several times per week or as prescribed by the treating physician to maintain protective factor levels. |
| Evidence status | Effectiveness and safety specifically in VWD or VWD/hemophilia A are still under study; results from this trial and case reports will inform future guidance, but published long-term data in these populations are limited. | Extensive published studies and current guidelines support their use in reducing bleeding risk and improving quality of life among people with severe VWD or VWD/hemophilia A who need prophylaxis. |
| Important limitations | Risks and benefits in VWD/hemophilia A remain unclear due to the lack of completed clinical trials; potential for unrecognized complications in this patient group since most data are from hemophilia A. Ongoing monitoring is essential. | Requires regular intravenous infusions, posing challenges for adherence and venous access, especially in young children or those with difficult veins. Allergic reactions, inhibitor development, and high treatment burden remain concerns. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 year
Participants receive subcutaneous injections of emicizumab as a prophylactic treatment for severe Von Willebrand Disease or VWD with Hemophilia A. The treatment starts with a weekly loading dose for 4 weeks, followed by weekly maintenance doses for up to 1 year. Dose adjustments may occur after 24 weeks if needed.
Weekly visits during the first 4 weeks, then weekly visits for maintenance dosing
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
A B Federici
https://pubmed.ncbi.nlm.nih.gov/26081061/Gallia G Levy, Elina Asikanius, Peter Kuebler...
https://pubmed.ncbi.nlm.nih.gov/31124272/Paula D James, Nathan T Connell, Barbara Ameer...
https://pubmed.ncbi.nlm.nih.gov/33570651/A Casonato, E Pontara, M Boscaro...
https://pubmed.ncbi.nlm.nih.gov/8339998/Midori Shima, Hideji Hanabusa, Masashi Taki...
https://pubmed.ncbi.nlm.nih.gov/27223146/Nathan T Connell, Veronica H Flood, Romina Brignardello-Petersen...
https://pubmed.ncbi.nlm.nih.gov/33570647/Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei...
https://pubmed.ncbi.nlm.nih.gov/23023498/Angela C Weyand, Veronica H Flood, Jordan A Shavit...
https://pubmed.ncbi.nlm.nih.gov/31540901/F Rodeghiero, G Castaman, E Dini
https://pubmed.ncbi.nlm.nih.gov/3492222/Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel...
https://pubmed.ncbi.nlm.nih.gov/30157389/Bleeding and Clotting Disorders Institute Peoria, Illinois
Lead Sponsor
Genentech, Inc.
Collaborating Sponsor